• Sep 15, 2026

  $267.20+0.33%

• Sep 14, 2026

  $266.32+0.28%

  Comparable pharmaceutical companies rose 1.06% on average, with 5 of 6 names gaining ground [1]. JNJ's 0.28% gain trailed this broader sector move [1].

  • 1Peer group

• Sep 11, 2026

  $265.58-0.29%

  Reports said Apollo Global Management was in talks to acquire J&J's DePuy Synthes orthopedics unit in a deal that could value it at close to $20B, according to Bloomberg as cited by Seeking Alpha [1].

  • 1Seeking Alpha

• Sep 10, 2026

  $266.35-0.27%

  Johnson & Johnson won a CE mark for its new ACUVUE contact lens as it nears a European launch [1].

  • 1Seeking Alpha

• Sep 9, 2026

  $267.08-0.76%

• Sep 8, 2026

  $269.12-2.22%

  Shares fell 2.22% as comparable pharmaceutical preparations companies also declined, averaging -2.42% with all six falling [1].

  • 1Peer group

• Sep 4, 2026

  $275.23-1.15%

  JNJ shares fell 1.15%, a move consistent with declines across comparable pharmaceutical companies, which dropped 1.24% on average, with all six peers tracked lower [1].

  • 1Peer group

Closing prices for JNJ. Summaries describe past sessions only and are not advice, a forecast or a recommendation.

Headlines are published by third parties and linked as reported. Amaltash does not endorse or verify them.